Cite
HARVARD Citation
Tabernero, J. et al. (2018). Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study. Lancet oncology. 19 (10), pp. 1372-1384. [Online].